258 related articles for article (PubMed ID: 35583829)
21. Epidemiology and outcome of invasive fungal disease in children after hematopoietic cell transplantation or treated for malignancy: Impact of national programme of antifungal prophylaxis.
Czyżewski K; Gałązka P; Frączkiewicz J; Salamonowicz M; Szmydki-Baran A; Zając-Spychała O; Gryniewicz-Kwiatkowska O; Zalas-Więcek P; Chełmecka-Wiktorczyk L; Irga-Jaworska N; Bień E; Ociepa T; Wawryków P; Tomaszewska R; Płonowski M; Pierlejewski F; Gamrot-Pyka Z; Małas Z; Urbanek-Dądela A; Stolpa W; Zaucha-Prażmo A; Goździk J; Chaber R; Gil L; Styczyński J
Mycoses; 2019 Nov; 62(11):990-998. PubMed ID: 31429997
[TBL] [Abstract][Full Text] [Related]
22. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.
Gomes MZ; Mulanovich VE; Jiang Y; Lewis RE; Kontoyiannis DP
Antimicrob Agents Chemother; 2014; 58(2):865-73. PubMed ID: 24277033
[TBL] [Abstract][Full Text] [Related]
23. The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent.
Ozga M; Huang Y; Blachly JS; Grieselhuber NR; Wall S; Larkin K; Haque T; Walker AR; Bhatnagar B; Behbehani G; Vasu S; Maakaron JE; Lustberg M; Mims AS
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e76-e83. PubMed ID: 32921593
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study.
Mariette C; Tavernier E; Hocquet D; Huynh A; Isnard F; Legrand F; Lhéritier V; Raffoux E; Dombret H; Ifrah N; Cahn JY; Thiébaut A
Leuk Lymphoma; 2017 Mar; 58(3):586-593. PubMed ID: 27397551
[TBL] [Abstract][Full Text] [Related]
25. The impact of antifungal prophylaxis in patients diagnosed with acute leukemias undergoing induction chemotherapy: a systematic review and meta-analysis.
Soldi LR; Coelho YNB; Paranhos LR; Silva MJB
Clin Exp Med; 2023 Nov; 23(7):3231-3249. PubMed ID: 37058186
[TBL] [Abstract][Full Text] [Related]
26. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
27. Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study.
Wang L; Wang Y; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Front Med; 2019 Jun; 13(3):365-377. PubMed ID: 30604166
[TBL] [Abstract][Full Text] [Related]
28. Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia.
Tu S; Zhang K; Wang N; Chu J; Yang L; Xie Z
Sci Rep; 2023 Nov; 13(1):18789. PubMed ID: 37914820
[TBL] [Abstract][Full Text] [Related]
29. Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management.
Girmenia C; Busca A; Candoni A; Cesaro S; Luppi M; Nosari AM; Pagano L; Rossi G; Venditti A; Aversa F
Med Mycol; 2019 Apr; 57(Supplement_2):S127-S137. PubMed ID: 30816979
[TBL] [Abstract][Full Text] [Related]
30. Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002-2018 Empirical/Pre-emptive Approach.
Martino R; Garrido A; Santaliestra M; García-Cadenas I; Novelli S; Saavedra SD; Esquirol A; Granell M; Briones J; Moreno C; Brunet S; Giménez A; Hidalgo A; Sánchez F; Sierra J
Mycopathologia; 2020 Aug; 185(4):639-652. PubMed ID: 32564177
[TBL] [Abstract][Full Text] [Related]
31. Invasive Aspergillosis in Patients with Acute Leukemia: Comparison Between Acute Myeloid and Acute Lymphoid Leukemia.
Colombo AL; Bergamasco MD; Nouér SA; Oliveira E Castro PT; Pasqualotto AC; de Queiroz-Telles F; Abdala E; Ramos JF; Falci DR; Nucci M
Mycopathologia; 2023 Apr; 188(1-2):1-8. PubMed ID: 36316599
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia.
Le Clech L; Uguen M; Quinio D; Nevez G; Couturier MA; Ianotto JC; Berthou C; Guillerm G; Le Bars H; Payan C; Narbonne V; Baron R; Saliou P
Curr Res Transl Med; 2020 Jan; 68(1):23-28. PubMed ID: 31787568
[TBL] [Abstract][Full Text] [Related]
33. Primary fungal prophylaxis in acute leukemia patients with different risk factors: retrospective analysis from the CAESAR study.
Zhang R; Chen J; Huang H; Ma J; Meng F; Tang Y; Hu J; Zhang X; Ji Y; Ai H; Liang Y; Wu D; Huang X; Han M
Int J Hematol; 2017 Aug; 106(2):221-228. PubMed ID: 28390035
[TBL] [Abstract][Full Text] [Related]
34. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
[TBL] [Abstract][Full Text] [Related]
35. Fungal infections in pediatric patients with acute myeloid leukemia in a tertiary hospital.
Ávila Montiel D; Saucedo Campos A; Avilés Robles M; Murillo Maldonado MA; Jiménez Juárez R; Silva Dirzo M; Dorantes Acosta E
Front Public Health; 2023; 11():1056489. PubMed ID: 37033052
[TBL] [Abstract][Full Text] [Related]
36. Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy.
Ballo O; Eladly F; Büttner S; Stratmann JA; Rudolf S; Brunnberg U; Kreisel EM; Steffen B; Wagner S; Finkelmeier F; Serve H; Brandts CH
Ann Hematol; 2021 May; 100(5):1159-1167. PubMed ID: 33704529
[TBL] [Abstract][Full Text] [Related]
37. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
38. The Addition of Hypomethylating Agents to Low-Intensity Induction Chemotherapy Does Not Improve Outcomes in Elderly Acute Myeloid Leukemia Patients: A Single-Center Retrospective Study.
Liu D; Wang X; Tong J; Zhou L; Chen E; Zhou Z; Xue L; Zhang X; Sun G; Zheng C
Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676738
[No Abstract] [Full Text] [Related]
39. 'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.
Del Principe MI; Dragonetti G; Verga L; Candoni A; Marchesi F; Cattaneo C; Delia M; Potenza L; Farina F; Ballanti S; Decembrino N; Castagnola C; Nadali G; Fanci R; Orciulo E; Veggia B; Offidani M; Melillo L; Manetta S; Tumbarello M; Venditti A; Busca A; Aversa F; Pagano L;
J Antimicrob Chemother; 2019 Apr; 74(4):1062-1068. PubMed ID: 30649413
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia.
Machherndl-Spandl S; Vockenhuber T; Binder M; Weltermann A; Apfalter P; Lass-Flörl C; Girschikofsky M
Leuk Lymphoma; 2022 Oct; 63(10):2330-2335. PubMed ID: 35561263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
